Todos Medical Ltd. announced it has completed the acquisition of all 3CL protease biology-related assets and formed a majority-owned subsidiary called 3CL Pharma Ltd. (3CL Pharma). 3CL Pharma will focus on developing therapeutics, diagnostics and dietary supplements based on 3CL protease (3CLpro, Main Protease, Mpro, Nsp5) biology related work of Dr. Dorit Arad, who joins Todos Medical as the newly appointed Chief Scientific Officer. Dr. Arad brings extensive experience and access to discoveries related to the development and commercialization of new chemical entities targeting the 3CL protease.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | 0.00% | 0.00% | -99.50% |
1st Jan change | Capi. | |
---|---|---|
-99.50% | 3.32K | |
-26.90% | 9.98B | |
-16.78% | 2.75B | |
-17.50% | 2.07B | |
-24.25% | 1.59B | |
+64.58% | 1.43B | |
+31.92% | 824M | |
-5.02% | 733M | |
-29.59% | 508M | |
+0.20% | 296M |
- Stock Market
- Equities
- TOMDF Stock
- News Todos Medical Ltd.
- Dorit Arad Joins Todos Medical as Chief Scientific Officer